<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00110708</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol 004</org_study_id>
    <nct_id>NCT00110708</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism</brief_title>
  <official_title>A Randomized, Placebo-Controlled Phase II Trial Evaluating Safety and Efficacy of Oral Human Immunoglobulin in the Treatment of Gastrointestinal Dysfunction Associated With Autistic Disorder in Pediatric Patients From 2 to 18 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PediaMed Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PediaMed Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if human immunoglobulin given by mouth twice a day&#xD;
      is effective in treating the persistent gastrointestinal (GI) problems such as diarrhea,&#xD;
      constipation, abdominal pain, and bloating, in children with autism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autistic GI Dysfunction (AGID) is a term that describes a constellation of GI signs and&#xD;
      symptoms often found in children with autistic disorder, including abdominal pain,&#xD;
      constipation, chronic diarrhea, alternating constipation and diarrhea, gaseousness, bloating,&#xD;
      and reflux.&#xD;
&#xD;
      The objective of this study is to assess the potential efficacy of oral immunoglobulin in&#xD;
      reducing a wide range of GI symptoms in children and adolescents diagnosed with autistic&#xD;
      disorder.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2005</start_date>
  <completion_date>June 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global improvement in gastrointestinal function</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of behavior (improvement and severity); additional assessments of gastrointestinal conditions</measure>
  </secondary_outcome>
  <enrollment>120</enrollment>
  <condition>Autism</condition>
  <condition>Autistic Disorder</condition>
  <condition>Child Development Disorders, Pervasive</condition>
  <condition>Gastrointestinal Diseases</condition>
  <condition>Signs and Symptoms, Digestive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oralgam (human immunoglobulin)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female from 2 years to 18 years of age (up to, but not inclusive of the 18th&#xD;
             birthday)&#xD;
&#xD;
          -  Diagnosis of autistic disorder corroborated by an Autism Diagnostic Interview -&#xD;
             Revised (ADI-R) assessment performed by a certified investigator&#xD;
&#xD;
          -  Physician Clinical Global Impression of Severity (of Autistic Disorder)&#xD;
&#xD;
          -  History of chronic, persistent gastrointestinal disturbance&#xD;
&#xD;
          -  No elective changes in medication, diet intervention, or behavioral therapy during the&#xD;
             study (18 weeks total)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of a gastrointestinal infection or GI abnormality&#xD;
&#xD;
          -  A known diagnosis of other gastrointestinal pathology&#xD;
&#xD;
          -  Antibiotic and/or antifungal (e.g. nystatin) medication&#xD;
&#xD;
          -  Chelation therapy&#xD;
&#xD;
          -  Medication affecting gastrointestinal transit&#xD;
&#xD;
          -  Planned use of prohibited drugs or agents that could affect GI transit&#xD;
&#xD;
          -  Changes in diet intervention within 30 days prior to the screening visit&#xD;
&#xD;
          -  Changes in alternative medical therapies or dietary supplements within 30 days prior&#xD;
             to the screening visit&#xD;
&#xD;
          -  Adding and/or changing behavior modification or psychotherapy during participation in&#xD;
             the study&#xD;
&#xD;
          -  Adding or changing psychotropic medication during participation in the study&#xD;
&#xD;
          -  DSM-IV diagnosis of a pervasive developmental disorder other than autistic disorder&#xD;
&#xD;
          -  Evidence of a seizure disorder, diagnosis of fragile X syndrome, tuberous sclerosis&#xD;
             complex, liver disease, pancreatic disease, cystic fibrosis, or chronic infection&#xD;
&#xD;
          -  Previous gastrointestinal surgery&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Participation in another investigational study&#xD;
&#xD;
          -  Significant deviation from normal laboratory test values at baseline&#xD;
&#xD;
          -  IgA deficiency (serum IgA &lt; 5 mg/dL)&#xD;
&#xD;
          -  A history of severe hypersensitivity to human immunoglobulin&#xD;
&#xD;
          -  Treatment with any human immunoglobulin and/or immunoglobulin products&#xD;
&#xD;
          -  Any concurrent medication that would compromise subject's tolerance of drug or&#xD;
             compliance with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Southwest Autism Research and Resource Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Autism Research and Education</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis, MIND Institute</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarkis Clinical Trials</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida HSC</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Child Development Resource Center</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Group of Central Florida</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center, Developmental Disabilities Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluegrass Clinical Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Research, LLC</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hardy Health Associates</name>
      <address>
        <city>Hingham</city>
        <state>Massachusetts</state>
        <zip>02043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pivotal Research Centers - Detroit</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson Medical School</name>
      <address>
        <city>Piscataway</city>
        <state>New Jersey</state>
        <zip>08854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strong Center for Developmental Disabilities, University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Center of Akron</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nisonger Center Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merck Child Outpatient Clinic</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North San Antonio Healthcare Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Autism Spectrum Treatment and Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2006</verification_date>
  <study_first_submitted>May 12, 2005</study_first_submitted>
  <study_first_submitted_qc>May 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2005</study_first_posted>
  <last_update_submitted>February 20, 2006</last_update_submitted>
  <last_update_submitted_qc>February 20, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2006</last_update_posted>
  <keyword>autism</keyword>
  <keyword>gastrointestinal dysfunction</keyword>
  <keyword>autistic disorder</keyword>
  <keyword>diarrhea</keyword>
  <keyword>constipation</keyword>
  <keyword>abdominal pain</keyword>
  <keyword>gastrointestinal problems associated with autism</keyword>
  <keyword>immune globulin</keyword>
  <keyword>immunoglobulin</keyword>
  <keyword>Immunoglobulins, Intravenous</keyword>
  <keyword>Intestinal Mucosa/immunology/pathology</keyword>
  <keyword>Administration, Oral</keyword>
  <keyword>Autistic Disorder/*drug therapy</keyword>
  <keyword>Child Behavior/*drug effects</keyword>
  <keyword>Constipation/drug therapy</keyword>
  <keyword>Diarrhea/drug therapy</keyword>
  <keyword>Gastrointestinal Agents/*therapeutic use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Signs and Symptoms, Digestive</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Developmental Disabilities</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

